137 related articles for article (PubMed ID: 9692458)
21. Comparative study of biocompatibility between the open circuit and closed circuit in cardiopulmonary bypass.
Nishida H; Aomi S; Tomizawa Y; Endo M; Koyanagi H; Nojiri C; Oshiyama H; Kido T; Yokoyama K
Artif Organs; 1999 Jun; 23(6):547-51. PubMed ID: 10392283
[TBL] [Abstract][Full Text] [Related]
22. Heparin-coated cardiopulmonary bypass equipment. I. Biocompatibility markers and development of complications in a high-risk population.
Videm V; Mollnes TE; Fosse E; Mohr B; Bergh K; Hagve TA; Aasen AO; Svennevig JL
J Thorac Cardiovasc Surg; 1999 Apr; 117(4):794-802. PubMed ID: 10096976
[TBL] [Abstract][Full Text] [Related]
23. Pro: heparin-bonded circuits represent a desirable option for cardiopulmonary bypass.
Shore-Lesserson L
J Cardiothorac Vasc Anesth; 1998 Dec; 12(6):705-9. PubMed ID: 9854673
[No Abstract] [Full Text] [Related]
24. Evaluation of heparin-coated circuits with full heparin dose strategy.
Sinci V; Kalaycioglu S; Gunaydin S; Imren Y; Gokgoz L; Soncul H; Ersoz A
Ann Thorac Cardiovasc Surg; 1999 Jun; 5(3):156-63. PubMed ID: 10413761
[TBL] [Abstract][Full Text] [Related]
25. Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass.
Gu YJ; van Oeveren W; Akkerman C; Boonstra PW; Huyzen RJ; Wildevuur CR
Ann Thorac Surg; 1993 Apr; 55(4):917-22. PubMed ID: 8466349
[TBL] [Abstract][Full Text] [Related]
26. Complete heparin-coated (CBAS) cardiopulmonary bypass and reduced systemic heparin dose; effects on coagulation and fibrinolysis.
Ovrum E; Brosstad F; Am Holen E; Tangen G; Abdelnoor M; Oystese R
Eur J Cardiothorac Surg; 1996; 10(6):449-55. PubMed ID: 8817142
[TBL] [Abstract][Full Text] [Related]
27. Duraflo II coating of cardiopulmonary bypass circuits reduces complement activation, but does not affect the release of granulocyte enzymes : a European multicentre study.
Fosse E; Thelin S; Svennevig JL; Jansen P; Mollnes TE; Hack E; Venge P; Moen O; Brockmeier V; Dregelid E; Haldén E; Hagman L; Videm V; Pedersen T; Mohr B
Eur J Cardiothorac Surg; 1997 Feb; 11(2):320-7. PubMed ID: 9080162
[TBL] [Abstract][Full Text] [Related]
28. Inflammatory response to cardiopulmonary bypass using two different types of heparin-coated extracorporeal circuits.
Baufreton C; Moczar M; Intrator L; Jansen PG; te Velthuis H; Le Besnerais P; Farcet JP; Wildevuur CR; Loisance DY
Perfusion; 1998 Nov; 13(6):419-27. PubMed ID: 9881389
[TBL] [Abstract][Full Text] [Related]
29. Impact of Heparin- or Nonheparin-Coated Circuits on Platelet Function in Pediatric Cardiac Surgery.
Giorni C; Pezzella C; Bojan M; Ricci Z; Pouard P; Raisky O; Tourneur L; La Salvia O; Favia I; Borgel D; Cogo P; Carotti A; Lasne D
Ann Thorac Surg; 2019 Apr; 107(4):1241-1247. PubMed ID: 30395857
[TBL] [Abstract][Full Text] [Related]
30. Impact of heparin bonding on pediatric cardiopulmonary bypass: a prospective randomized study.
Grossi EA; Kallenbach K; Chau S; Derivaux CC; Aguinaga MG; Steinberg BM; Kim D; Iyer S; Tayyarah M; Artman M; Galloway AC; Colvin SB
Ann Thorac Surg; 2000 Jul; 70(1):191-6. PubMed ID: 10921707
[TBL] [Abstract][Full Text] [Related]
31. A prospective randomized trial comparing the clinical effectiveness and biocompatibility of heparin-coated circuits and PMEA-coated circuits in pediatric cardiopulmonary bypass.
Itoh H; Ichiba S; Ujike Y; Douguchi T; Kasahara S; Arai S; Sano S
Perfusion; 2016 Apr; 31(3):247-54. PubMed ID: 26228276
[TBL] [Abstract][Full Text] [Related]
32. Release of lipopolysaccharide toxicity-modulating proteins in patients undergoing cardiopulmonary bypass using noncoated and heparin-coated extracorporeal circuits. A clinical pilot study.
Bouma M; Maessen J; Weerwind P; Dentener M; Fransen E; de Jong D; Buurman W
Chest; 1997 Mar; 111(3):577-83. PubMed ID: 9118690
[TBL] [Abstract][Full Text] [Related]
33. A prospective randomized trial of Duraflo II heparin-coated circuits in cardiac reoperations.
McCarthy PM; Yared JP; Foster RC; Ogella DA; Borsh JA; Cosgrove DM
Ann Thorac Surg; 1999 May; 67(5):1268-73. PubMed ID: 10355394
[TBL] [Abstract][Full Text] [Related]
34. Superior biocompatibility of heparin-bonded circuits in pediatric cardiopulmonary bypass.
Ozawa T; Yoshihara K; Koyama N; Yamazaki S; Takanashi Y
Jpn J Thorac Cardiovasc Surg; 1999 Dec; 47(12):592-9. PubMed ID: 10658376
[TBL] [Abstract][Full Text] [Related]
35. Endothelin-1 and neutrophil activation during heparin-coated cardiopulmonary bypass.
Lundblad R; Moen O; Fosse E
Ann Thorac Surg; 1997 May; 63(5):1361-7. PubMed ID: 9146328
[TBL] [Abstract][Full Text] [Related]
36. Heparin-coated cardiopulmonary bypass circuits: hemostatic alterations and postoperative blood loss.
Wagner WR; Johnson PC; Thompson KA; Marrone GC
Ann Thorac Surg; 1994 Sep; 58(3):734-40; discussion 741. PubMed ID: 7944696
[TBL] [Abstract][Full Text] [Related]
37. Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies.
Wan S; LeClerc JL; Vincent JL
Chest; 1997 Sep; 112(3):676-92. PubMed ID: 9315800
[TBL] [Abstract][Full Text] [Related]
38. Clinical and biomaterial evaluation of hyaluronan-based heparin-bonded extracorporeal circuits with reduced versus full systemic anticoagulation in reoperation for coronary revascularization.
Gunaydin S; Farsak B; McCusker K; Vijay V; Sari T; Onur MA; Gurpinar A; Zorlutuna Y
J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):135-42. PubMed ID: 19377380
[TBL] [Abstract][Full Text] [Related]
39. Heparin-coated cardiopulmonary bypass circuits: current status.
Hsu LC
Perfusion; 2001 Sep; 16(5):417-28. PubMed ID: 11565897
[TBL] [Abstract][Full Text] [Related]
40. The impact of heparin-coated circuits on hemodynamics during and after cardiopulmonary bypass.
de Vroege R; Huybregts R; van Oeveren W; van Klarenbosch J; Linley G; Mutlu J; Jansen E; Hack E; Eijsman L; Wildevuur C
Artif Organs; 2005 Jun; 29(6):490-7. PubMed ID: 15926987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
